BiotechTube

Emicizumab

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemophilia A

Conditions

Hemophilia A

Trial Timeline

Apr 30, 2026 → Jan 29, 2032

NCT ID
NCT07416604

About Emicizumab

Emicizumab is a phase 3 stage product being developed by Chugai Pharmaceutical for Hemophilia A. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07416604. Target conditions include Hemophilia A.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT07416604Phase 3Recruiting
NCT03020160Phase 3Completed
NCT02795767Phase 3Completed

Competing Products

20 competing products in Hemophilia A

See all competitors
ProductCompanyStageHype Score
EmicizumabChugai PharmaceuticalPhase 3
77
EmicizumabChugai PharmaceuticalPhase 3
77
Emicizumab + rFVIIa + aPCCChugai PharmaceuticalPhase 3
77
Human Coagulation Factor VIIIChugai PharmaceuticalPhase 3
77
Emicizumab + Factor VIII (FVIII)Chugai PharmaceuticalPhase 3
77
EmicizumabRochePhase 3
77
HEMLIBRAJohnson & JohnsonPre-clinical
23
EmicizumabRochePhase 3
77
EmicizumabRocheApproved
85
EmicizumabRochePhase 3
77
SPK-8011QQRochePhase 1/2
41
NXT007RochePhase 1/2
41
Emicizumab InjectionRochePhase 2
52
Bypassing Agents + FVIII ReplacementRochePre-clinical
23
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086PfizerPhase 2
51
Nonacog Alfa (Genetical Recombination)PfizerPre-clinical
22
Refacto AFPfizerPre-clinical
22
PF-06838435/ fidanacogene elaparvovecPfizerPhase 3
76
ReFacto AFPfizerPhase 3
76
Nonacog alfa + Nonacog alfaPfizerPhase 3
76

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77